Pancreatic cancer

JD Mizrahi, R Surana, JW Valle, RT Shroff - The Lancet, 2020 - thelancet.com
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Therapeutic developments in pancreatic cancer: current and future perspectives

JP Neoptolemos, J Kleeff, P Michl, E Costello… - Nature reviews …, 2018 - nature.com
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

[HTML][HTML] Challenges in diagnosis of pancreatic cancer

L Zhang, S Sanagapalli, A Stoita - World journal of …, 2018 - ncbi.nlm.nih.gov
Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates
which have not improved in the last few decades. Its high mortality rate is attributed to …

Pancreatic cancer

T Kamisawa, LD Wood, T Itoi, K Takaori - The Lancet, 2016 - thelancet.com
Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence.
Most patients with pancreatic cancer remain asymptomatic until the disease reaches an …

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Ducreux, AS Cuhna, C Caramella… - Annals of …, 2015 - annalsofoncology.org
A recent study estimating cancer epidemiology in 2014 (within Europe) showed that
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …

Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors

A Zinger, L Koren, O Adir, M Poley, M Alyan, Z Yaari… - ACS …, 2019 - ACS Publications
Overexpressed extracellular matrix (ECM) in pancreatic ductal adenocarcinoma (PDAC)
limits drug penetration into the tumor and is associated with poor prognosis. Here, we …

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

T Conroy, P Pfeiffer, V Vilgrain, A Lamarca… - Annals of …, 2023 - annalsofoncology.org
The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

An update on treatment options for pancreatic adenocarcinoma

A Lambert, L Schwarz, I Borbath… - … in medical oncology, 2019 - journals.sagepub.com
Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

M Mortazavi, F Moosavi, M Martini, E Giovannetti… - Critical reviews in …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

[HTML][HTML] Pancreatic cancer in 2021: What you need to know to win

V Tonini, M Zanni - World Journal of Gastroenterology, 2021 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …